














































Key words: 慢性気管支炎（chronic bronchitis），肺気腫（pulmonary emphysema），
 長時間作用性抗コリン薬（long-acting muscarinic antagonist），











































































































（Global Initiative for Chronic Obstructive Lung Disease）の
気流閉塞の重症度分類と一致しており，病期分類Ⅰ～Ⅳ











































































同 ラ ン ダ ム 化 比 較 試 験 で あ る National Emphysema 
























































































protein kinase （p₃₈ MAPK），phosphatidylinositol- ₃ -OH 
kinase （PI₃K）などに代表されるキナーゼ，酸化ストレス
およびプロテアーゼを標的とした薬剤，receptor for 























































接種諮問委員会（Advisory Committee on Immunization 
Practices; ACIP）は，これまでに肺炎球菌ワクチンの接種
歴が無い₆₅歳以上の成人に対して先にPCV₁₃を接種し，
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Abstract
WHAT IS COPD (CHRONIC OBSTRUCTIVE PULMONARY DISEASE),  
THE WORLDʼS THIRD LEADING CAUSE OF DEATH ?
Takeshi KaneKo
Department of Pulmonology, Yokohama City University Graduate School of Medicine
　Chronic Obstructive Pulmonary Disease (COPD), is a common disease but is not well recognized, and 
underdiagnosed, is characterized by persistent airflow limitation (%FEV₁ < ₇₀% after inhalation of bronchodilator). 
Respiratory function impairment is associated with a chronic inflammatory response in the peripheral airways and 
pulmonary parenchyma mainly due to long-term cigarette smoke exposure. Symptoms include cough, sputum, and 
dyspnea.
　The mainstays of drug therapy of stable symptomatic COPD are inhaled bronchodilators (long-acting β₂-agonists 
and long-acting muscarinic antagonists), and this pharmacotherapy is generally added in a stepwise fashion. 
However, current pharmacotherapy is ineffective for controlling disease totally. Pharmacotherapy targeting both the 
airway and systemic inflammation is necessary.
　Non-pharmacologic interventions are also important. Among these, smoking cessation is the most important and 
essential to reduce the disease progression. Pulmonary rehabilitation is effective for improving physical activity. 
Moreover, it has the benefit of decreasing dyspnea, improving exercise capacity, health-related quality of life, and 
ability of daily life.  In addition, pneumococcal vaccine and an annual influenza vaccine should be offered to patients 
with COPD, because respiratory tract infection is the most common cause of COPD exacerbation.
